Deciphera Pharmaceuticals Llc Stock Probability of Future Stock Price Finishing Under 25.36
| DCPH Stock | USD 25.55 0.03 0.12% |
Closest to current price Deciphera long CALL Option Payoff at Expiration
Deciphera |
Deciphera Pharmaceuticals Target Price Odds to finish below 25.36
The tendency of Deciphera Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 25.36 or more in 90 days |
| 25.55 | 90 days | 25.36 | about 87.09 |
Based on a normal probability distribution, the odds of Deciphera Pharmaceuticals to drop to $ 25.36 or more in 90 days from now is about 87.09 (This Deciphera Pharmaceuticals LLC probability density function shows the probability of Deciphera Stock to fall within a particular range of prices over 90 days) . Probability of Deciphera Pharmaceuticals price to stay between $ 25.36 and its current price of $25.55 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.83 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Deciphera Pharmaceuticals will likely underperform. Additionally Deciphera Pharmaceuticals LLC has an alpha of 0.866, implying that it can generate a 0.87 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta). Deciphera Pharmaceuticals Price Density |
| Price |
Predictive Modules for Deciphera Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Deciphera Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Deciphera Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Deciphera Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Deciphera Pharmaceuticals is not an exception. The market had few large corrections towards the Deciphera Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Deciphera Pharmaceuticals LLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Deciphera Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | 0.87 | |
β | Beta against NYSE Composite | 1.83 | |
σ | Overall volatility | 5.04 | |
Ir | Information ratio | 0.1 |
Deciphera Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Deciphera Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Deciphera Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Deciphera Pharmaceuticals is way too risky over 90 days horizon | |
| Deciphera Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 163.36 M. Net Loss for the year was (194.94 M) with loss before overhead, payroll, taxes, and interest of (62.55 M). | |
| Deciphera Pharmaceuticals LLC currently holds about 383.85 M in cash with (146.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Deciphera Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Armistice Capital LLC Raises Holdings in Deciphera Pharmaceuticals, Inc. - MarketBeat |
Deciphera Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Deciphera Stock often depends not only on the future outlook of the current and potential Deciphera Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Deciphera Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 85.1 M | |
| Cash And Short Term Investments | 306.2 M |
Deciphera Pharmaceuticals Technical Analysis
Deciphera Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Deciphera Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Deciphera Pharmaceuticals LLC. In general, you should focus on analyzing Deciphera Stock price patterns and their correlations with different microeconomic environments and drivers.
Deciphera Pharmaceuticals Predictive Forecast Models
Deciphera Pharmaceuticals' time-series forecasting models is one of many Deciphera Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Deciphera Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Deciphera Pharmaceuticals
Checking the ongoing alerts about Deciphera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Deciphera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Deciphera Pharmaceuticals is way too risky over 90 days horizon | |
| Deciphera Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 163.36 M. Net Loss for the year was (194.94 M) with loss before overhead, payroll, taxes, and interest of (62.55 M). | |
| Deciphera Pharmaceuticals LLC currently holds about 383.85 M in cash with (146.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Deciphera Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Armistice Capital LLC Raises Holdings in Deciphera Pharmaceuticals, Inc. - MarketBeat |
Additional Information and Resources on Investing in Deciphera Stock
When determining whether Deciphera Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Deciphera Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Deciphera Pharmaceuticals Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Deciphera Pharmaceuticals Llc Stock:Check out Deciphera Pharmaceuticals Backtesting, Deciphera Pharmaceuticals Valuation, Deciphera Pharmaceuticals Correlation, Deciphera Pharmaceuticals Hype Analysis, Deciphera Pharmaceuticals Volatility, Deciphera Pharmaceuticals History as well as Deciphera Pharmaceuticals Performance. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 2.028 | Quarterly Revenue Growth 0.345 | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.